Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical StudyNovember 19, 2024 7:45 AM EST | Source: Phio Pharmaceuticals Corp.--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a cancer-free future, today announced it has completed the enrollment of its ...

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 14, 2024 5:47 PM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells t ...

● . . Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT October 18, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effe ...

● ● . | --- | --- | |----------------------------------------------|-------| | | | | INSTAYL Compound PH-894 at ASGCT's 2024 | | | Advancing Gene and Cell Therapies for Cancer | | October 16, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. PH-894: Potent and Specific Silencing of BRD4 in NK Cells Marlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by usin ...

. . Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells October 07, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-T Marlborough, Massachusetts--(Newsfile Corp. - October 7, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make im ...

● . INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society --Data will be presented at the conference in October in Montreal September 25, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more eff ...

. . Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDT August 29, 2024 8:30 AM EDT | Source: Phio Pharmaceuticals Corp. Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effectiv ...

Core Insights - Phio Pharmaceuticals reported its financial results for Q2 2024, highlighting progress in its clinical trials and financial position [3][10]. Recent Corporate Updates - The Phase 1b clinical trial for PH-762 received a positive safety recommendation, with no dose-limiting toxicities observed, leading to dose escalation and enrollment of the next cohort [3][4]. - A fifth clinical trial site has been added at the University of Pittsburgh Medical Center, joining four other sites [5]. - A new patent for INTASYL RXI-185, targeting aging skin disorders, was granted in South Korea [6]. - The company entered into agreements to exercise warrants for 545,286 shares at a reduced price, generating approximately $3.1 million in gross proceeds [7][11]. - A reverse stock split was executed, reducing outstanding shares from approximately 4.6 million to 0.5 million [8]. - The company is now in compliance with Nasdaq's minimum bid price requirement [9]. - Robert M. Infarinato was appointed as the new CFO effective August 1, 2024 [9]. - An exploratory collaboration was initiated with a global skincare company for cosmeceutical applications [10]. Financial Results - Cash position decreased to $4.7 million as of June 30, 2024, down from $8.5 million at the end of 2023 [10]. - Research and development expenses were $0.9 million for Q2 2024, a 37% decrease from $1.4 million in Q2 2023 [12]. - General and administrative expenses decreased by 10% to $1.0 million in Q2 2024 compared to $1.2 million in Q2 2023 [13]. - The net loss for Q2 2024 was $1.8 million, down from $2.5 million in Q2 2023, primarily due to reduced expenses [14]. Operational Metrics - Total operating expenses for Q2 2024 were $1.9 million, compared to $2.5 million in Q2 2023 [19]. - The net loss per common share for Q2 2024 was $3.62, compared to $13.27 in Q2 2023 [19]. - The weighted average number of common shares outstanding was 510,188 for Q2 2024 [19]. Balance Sheet Highlights - Total assets as of June 30, 2024, were $5.3 million, down from $9.4 million at the end of 2023 [20][21]. - Cash and cash equivalents decreased to $4.7 million from $8.5 million [20]. - Total liabilities were $1.5 million, with total stockholders' equity at $3.8 million [21].

Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the appointment of Robert M. Infarinato to the position of vice president and chief financial officer effective August 1, 2024. He will serve in the capacity of Principal Financial Officer including responsibility for a ...

. July 12, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional $136,321.50 in the aggregate, which are included in the gross proceeds to the Company), the exercising holders will receive new unregistered warrants to purchase shares of common stock in a private placement pursuant ...